Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diagnostic methods for Helicobacter pylori detection and eradication.

A F Goddard1, R P H Logan

  • 1Derby City Hospital, Derby, UK.

British Journal of Clinical Pharmacology
|August 16, 2003
PubMed
Summary

Developing new treatments for Helicobacter pylori (H. pylori) infection is challenging due to resistance and delivery issues. Current therapies face hurdles, and while animal studies show promise for vaccines, human results are less encouraging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of 12-month surveillance colonoscopy in high-risk patients in the National Health Service Bowel Cancer Screening Programme.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England.

Endoscopy·2012
Same author

The misuse of the faecal occult blood test under the lower gastrointestinal two week wait rule.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2008
Same author

Referral of patients with iron deficiency anaemia under the lower gastrointestinal two-week wait rule.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2007
Same author

An unusual cause of abdominal pain.

Gut·2006
Same author

Immunosuppression, IBD, and risk of lymphoma.

Gut·2002

Area of Science:

  • Medical Microbiology
  • Gastroenterology
  • Pharmacology

Background:

  • Helicobacter pylori is a primary cause of peptic ulcer disease and a significant risk factor for gastric cancer.
  • Standard 1-week triple therapies for H. pylori infection can achieve high eradication rates (>90%) but are hampered by poor patient compliance and increasing antimicrobial resistance.
  • The unique gastric mucus niche of H. pylori presents challenges for drug delivery and the identification of novel therapeutic targets.

Purpose of the Study:

  • To highlight the challenges in developing new anti-H. pylori therapies.
  • To discuss the limitations of current treatment strategies and the need for novel approaches.
  • To review the status of animal models and vaccination strategies for H. pylori infection.

Main Methods:

Related Experiment Videos

  • Literature review of H. pylori treatment efficacy, resistance patterns, and drug delivery challenges.
  • Analysis of the clinical validity of current animal models for H. pylori infection.
  • Evaluation of vaccination strategies in animal models versus human studies.

Main Results:

  • Patient compliance and antimicrobial resistance significantly reduce the efficacy of existing H. pylori therapies.
  • Developing new therapies requires overcoming challenges in identifying novel targets and ensuring effective drug delivery to the gastric mucus.
  • While animal models for H. pylori infection exist, their clinical relevance is unproven. Vaccination has shown success in animals but not in human trials.

Conclusions:

  • New anti-H. pylori therapies are urgently needed, but their development faces significant pharmacological and logistical challenges.
  • Improving patient compliance and addressing antimicrobial resistance are critical for current H. pylori treatment strategies.
  • Further research is required to validate animal models and advance human vaccination efforts against H. pylori.